Management of Elevated Fibrinogen Levels

Understanding Elevated Fibrinogen

Fibrinogen functions as an acute phase reactant protein that increases during inflammatory processes, often rising alongside C-reactive protein (CRP) during inflammatory responses 1
Elevated fibrinogen is a significant independent risk marker in acute coronary syndromes and is associated with both short-term and long-term risk of death and subsequent myocardial infarction 1, 2
Normal fibrinogen levels typically range from 2.0-4.0 g/L, with levels above this considered elevated 3

Acute and chronic inflammatory diseases trigger fibrinogen elevation as part of the acute phase response 1
Cardiovascular diseases, particularly acute coronary syndromes, are associated with elevated fibrinogen 2
Trauma and tissue injury lead to increased fibrinogen production 4, 1

In the FRISC trial, elevated fibrinogen was associated with both short and long-term risk of death and subsequent myocardial infarction 2, 1

Measure fibrinogen levels using the Clauss method, recognizing that artificial colloids like hydroxyethyl starch can cause overestimation 3, 5
Consider viscoelastic monitoring (thromboelastometry/TEG) for more accurate assessment of fibrinogen function in critical care settings 4, 3

Fibrinogen levels physiologically increase during pregnancy 6
In pregnant women with congenital fibrinogen disorders, management differs significantly and requires specialized care 6

In trauma patients, fibrinogen levels should be maintained above 1.5-2.0 g/L to prevent bleeding complications 4, 7, 8
For ongoing bleeding in trauma, target fibrinogen levels of ≥1.5 g/L 8, 5
In cases of hypofibrinogenemia in trauma, fibrinogen concentrate (3-4g) or cryoprecipitate (50 mg/kg) may be administered 5

Regular monitoring of fibrinogen levels is recommended when treating conditions associated with elevated fibrinogen 4, 3
Goal-directed strategies using standard laboratory coagulation values, including fibrinogen, are recommended for managing bleeding in trauma patients 4, 1

The American Society of Anesthesiologists recommends considering viscoelastic monitoring to guide fibrinogen replacement, targeting levels >1.5 g/L in bleeding patients 9
The Critical Care society suggests that fibrinogen levels should not be used to guide anticoagulation intensity, but rather to assess coagulation status 10

The American College of Cardiology recommends assessing the indication for anticoagulation using standard risk stratification tools, and recognizing that elevated fibrinogen increases thrombotic risk, which may strengthen the indication for anticoagulation rather than contraindicate it 11
The Critical Care society recommends monitoring standard anticoagulation parameters, such as INR for warfarin, and anti-Xa levels for DOACs when indicated, rather than fibrinogen levels 12

The Critical Care society recommends continuing anticoagulation as indicated by the primary condition in patients on therapeutic anticoagulation with elevated fibrinogen, and that elevated fibrinogen reflects increased cardiovascular risk and does not require dose adjustment of anticoagulants 13
The American Society of Anesthesiologists recommends considering prothrombin complex concentrates (PCCs) in patients with excessive bleeding and elevated INR on warfarin 11

The Anaesthesia society recommends measuring fibrinogen using the Clauss method when assessing coagulation status, recognizing that artificial colloids like hydroxyethyl starch can cause overestimation 9
The Critical Care society recommends using viscoelastic monitoring to guide fibrinogen replacement, targeting levels >1.5 g/L in bleeding patients 12

During pregnancy, fibrinogen levels normally increase, reaching 3.7 to 6.2 g/L during the third trimester, with median levels of 3.86 g/L at 36 weeks, and D-dimer levels up to 2 μg/mL can still be within normal range for pregnant women, as noted by the Journal of Thrombosis and Haemostasis 14
Elevated fibrinogen in pregnancy is physiological and expected, not pathological, with fibrinogen levels increasing progressively throughout pregnancy 14
In deteriorating COVID-19 patients developing coagulopathy, fibrinogen levels paradoxically decrease, signaling consumption and poor prognosis, as reported in the Journal of Thrombosis and Haemostasis 14

The Clauss method is the preferred laboratory technique for measuring fibrinogen, though artificial colloids like hydroxyethyl starch cause significant overestimation 15, 16, 17
Fibrinogen <100 mg/dL (1.0 g/L) in cirrhotic patients is associated with spontaneous and procedure-related bleeding 18

In bleeding trauma patients, administer fibrinogen concentrate 3-4 g or cryoprecipitate 50 mg/kg to target levels ≥1.5-2.0 g/L 15, 16, 17
In cirrhosis with bleeding, consider replacement if <100 mg/dL (1.0 g/L), though causal relationships with bleeding are not established 18
Use viscoelastic monitoring (thromboelastometry) for more accurate functional assessment than laboratory values alone 15, 16, 17

In congenital fibrinogen disorders during pregnancy, target trough levels ≥1.0 g/L throughout pregnancy, increasing to ≥1.5 g/L with vaginal bleeding 19

Elevated fibrinogen adds independent prognostic information beyond ECG findings and troponin levels in acute coronary syndromes 20
The association with long-term mortality is particularly strong, contrasting with its relationship to acute myocardial infarction 20
Assess cardiovascular risk: elevated fibrinogen independently increases thrombotic risk requiring standard risk stratification 20